Close this search box.

Congress flatlines FDA budget

ARTICLE | Politics, Policy & Law

Medical product reviews unlikely to be impacted

By Steve Usdin, Washington editor

March 4, 2024 8:02 PM UTC

A bipartisan budget deal announced Sunday is disappointing for FDA, but is unlikely to impact the agency’s ability to review medical products, which are largely funded by user fees.

Congress is poised to flat fund FDA, leaving its FY24 budget appropriation at the same level as FY23. In practice, this would force cutbacks because the agency must find $105 million to cover a mandatory pay increase, Steven Grossman, executive director of the Alliance for a Stronger FDA, told BioCentury.